Thera-SAbDab

RIVABAZUMAB

>   Structural Summary
TherapeuticRivabazumab
TargetPcrV type III secretion system
Heavy ChainEVQLVESGGGVVQPGRSLRLSCAASGFTFSNYPMHWVRQAPGKGLEWVAVISYDGSEKWYADSVKGRFTISRDNSKNTLYLEMNSLRPEDTAVYYCARNRGDIYYDFTYAMDIWGQGTTVTVSS
Light ChainDIQLTQSPSTLSASVGDSVTITCRASEGVDRWLAWYQQKPGRAPKLLIYDASTLQSGVPSRFSGSGSGTEFSLTISSLQPDDVATYYCQHFWGTPYTFGQGTKLEIK
100% seqID Fv StructureNone
99% seqID Fv StructureNone
95-98% seqID Fv StructureNone
>   Metadata
FormatFab
IsotypeG1
Highest Clinical Trial (June '19)Phase-II
Estimated Status (June '19)Discontinued
Recorded Developmental TechnologyHumaneering Technology
INN Year Proposed2015
INN Year Recommended2016
Companies InvolvedKaloBios Pharmaceuticals Inc
Conditions Approvedna
Conditions Activena
Conditions DiscontinuedInfectiology, Inflammation, Inherited diseases
Notes

SAbDab paper: Dunbar, J., Krawczyk, K. et al (2014). Nucleic Acids Res. 42. D1140-D1146 [link]

Thera-SAbDab paper: Raybould, M.I.J., Marks, C. et al (2019). Nucleic Acids Res. gkz827 [link]